Minnesota Valley Health Center Inc Medicare and Medicaid Location: 621 South 4th Street, Le Sueur, Minnesota 56058 Ratings: Phone: (507) 665-3375 |
News Archive
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today an exclusive partnership agreement with Therabel Group for the European commercialization rights of Loramyc® and Setofilm® including France and the associated French commercial structure to a newly established entity, Therabel Hôpital Pharma.
"There will be an opportunity for the public to provide input on breast implants and no regulatory decisions have been made at this point. My officials have been looking at several models over the last few weeks to determine how best to receive public input," the Minister said.
Placement of an endovascular stent has become a common procedure to successfully reopen blocked arteries. Even so, the treated vessel may once again narrow (restenosis), restricting blood flow. In the femoral and popliteal arteries in the leg, the use of nitinol stents magnifies this problem. About 20 to 40 percent of these stent patients experience restenosis 2 years after angioplasty. Now, an improved radiation technique may provide a safe and effective solution.
› Verified 1 days ago